Ampersand buys AccuMed after merger talks fail:
This article was originally published in Clinica
AccuMed has signed a definitive agreement to be acquired by Ampersand Medical in a share deal, three months after Ampersand terminated merger negotiations between the two companies. At that time, the companies agreed to discuss further possibilities (see Clinica No 938, p 12). Ampersand is a cancer diagnostic company and uses AccuMed's AcCell automated microscopy technology in clinical trials of its InPath cervical cancer detection system. Both companies are based in Chicago.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.